Open AccessThe role of second generation Bruton tyrosine kinase inhibitors in the treatment of chronic lymphocytic leukemia. Resolution
Author(s) -
I V Poddubnaya,
Поддубная Ирина Владимировна,
Т. Е. Бялик,
Бялик Татьяна Евгеньевна,
Natalya N. Glonina,
Глонина Наталья Николаевна,
Olga Kalashnikova,
Калашникова Ольга Борисовна,
Kamil Kaplanov,
Капланов Камиль Даниялович,
В. А. Лапин,
Лапин Валерий Альбертович,
Nadezhda V. Medvedeva,
Медведева Надежда Вадимовна,
Н. Б. Михайлова,
Михайлова Наталья Борисовна,
Tatyana Moiseeva,
Моисеева Татьяна Николаевна,
Е.С. Никитин,
Никитин Евгений Александрович,
Т И Поспелова,
Поспелова Татьяна Ивановна,
Elena Stadnik,
Стадник Елена Александровна
Publication year - 2020
Publication title -
sovremennaâ onkologiâ
Language(s) - English
Resource type - Journals
eISSN - 1815-1442
pISSN - 1815-1434
DOI - 10.26442/18151434.2019.4.190725
Subject(s) - chronic lymphocytic leukemia , bruton's tyrosine kinase , medicine , tyrosine kinase , leukemia , first line treatment , ibrutinib , disease , oncology , immunology , chemotherapy , receptor
Chronic lymphocytic leukemia (CLL) is the most common type of adult leukemia, with incidence rate of 4: 100 thousand per year, according to European data. CLL remains an incurable disease, with most patients over 60 years old. Immunochemotherapy schemes today remain the standard treatment approach for CLL. The advent of novel molecules expands possibilities of treating this disease. Targeted therapy with small molecule inhibitors of Bruton tyrosine kinase (BTK) occupies an important place in the treatment of patients with CLL, both for first-line therapy and for treatment of relapses. The drug acalabrutinib as a highly selective new generation of BTK inhibitor can be considered as an efficient and safe option for first-line therapy and for treatment of the disease relapse in patients with CLL, especially in patients with comorbidity, including cardiovascular diseases (CDV) or risk factors for CVD.